GT Biopharma, Inc.

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-14 pm EDT			5-day change	1st Jan Change
3.193 ^USD	-1.74%		-1.14%	-58.26%

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 05:01 pm EDT

GT Biopharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 20.88 million compared to USD 58.01 million a year ago. Basic loss per share from continuing operations was USD 19.8 compared to USD 61.8001 a year ago.

Latest news about GT Biopharma, Inc.

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01	MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index	23-06-23	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
GT Biopharma, Inc. Announces Board Changes	23-05-04	CI
Certain Warrants of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
Certain Common Stock of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
North American Morning Briefing : Traders Await -3-	23-03-31	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -2-	23-03-24	DJ
Beyond Air Affiliate Beyond Cancer Names Gavin Choy Chief Operating Officer	23-01-30	MT
EF Hutton Starts GT Biopharma at Hold With $2 Price Target	23-01-05	MT
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	22-12-30	MT
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	22-12-14	CI
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	22-12-13	CI
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	22-12-12	MT
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI

Chart GT Biopharma, Inc.

Duration

Period

More charts

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.193 USD

Average target price

150 USD

Spread / Average Target

+4,597.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GT BIOPHARMA, INC.	-58.26%	4.49M
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals

GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Pharmaceuticals

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

Latest news about GT Biopharma, Inc.

Chart GT Biopharma, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals